Organon & Co (OGN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $3.65B
Last updated: Nov 17, 2026 at 11:06 AM ET
Organon & Co (OGN) Stock Forecast
Analysts expect Organon (OGN) to earn $3.44 per share in the fiscal year ending Dec 31, 2026, on revenue of $6.16B. Of 5 analysts, 0 rate the stock Buy or Strong Buy, 4 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 3.40, inside the Hold band from 2.5 up to 3.5. Sell and Strong Sell make up 20% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 0 | 0.0% |
| Hold | 4 | 80.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 20.0% |
- Consensus
- Hold
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 6.1% and revenue estimates rise 2.1%.
- Fiscal year ending Dec 31, 2026
- $3.44
- EPS consensus, revenue $6.16B
- Fiscal year ending Dec 31, 2027
- $3.65
- EPS consensus, revenue $6.29B
- Next report
- Feb 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $3.44 | $3.30 to $3.72 | 4 | $6.16B | $6.13B to $6.17B | 3 |
| Dec 31, 2027 | $3.65 | $3.55 to $3.82 | 4 | $6.29B | $6.24B to $6.36B | 3 |
Quarterly Estimates
The EPS consensus rises from $0.80 for the quarter ending Dec 31, 2026 to $0.92 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.80 | $0.64 to $0.97 | 9 | $1.56B | $1.51B to $1.62B | 6 |
| Mar 31, 2027 | $0.92 | $0.90 to $0.94 | 2 | $1.53B | $1.53B to $1.53B | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 3 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 5.0% from $3.62.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $3.44 | $3.36 | $3.43 | $3.43 | $3.62 | -5.1% |
| Fiscal year ending Dec 31, 2027 | $3.65 | $3.62 | $3.62 | $3.62 | $3.64 | +0.3% |
| Quarter ending Mar 31, 2027 | $0.92 | $0.88 | $0.88 | $0.88 | $0.88 | +5.0% |
Frequently Asked Questions About OGN
What is the OGN stock forecast?
Consensus analyst estimates put Organon's EPS at $3.44 for the fiscal year ending Dec 31, 2026, on revenue of $6.16B. The consensus rating from 5 analysts is Hold.
How do analysts rate OGN stock?
Of 5 analysts covering Organon, 0 rate it Strong Buy, 0 Buy, 4 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from OGN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $3.44, with estimates from $3.30 to $3.72 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.65, with estimates from $3.55 to $3.82 from 4 analysts.
What revenue do analysts expect from Organon next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $6.16B, with estimates from $6.13B to $6.17B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $6.29B, with estimates from $6.24B to $6.36B.
How many analysts cover OGN?
5 analysts rate Organon stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
OGN pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors